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We have recently demonstrated that amino acid region 323–331 of factor Va heavy chain (9 amino acids,
AP4ⴕ) contains a binding site for factor Xa (Kalafatis, M.,
and Beck, D. O. (2002) Biochemistry 41, 12715–12728). To
ascertain which amino acids within this region are important for the effector and receptor properties of the
cofactor with respect to factor Xa, we have synthesized
three overlapping peptides (5 amino acids each) spanning the amino acid region 323–331 and tested them for
their effect on prothrombinase complex assembly and
function. Peptide containing amino acids 323EYFIA327
alone was found to increase the catalytic efficiency of
factor Xa but had no effect on the fluorescent anisotropy
of active site-labeled factor Xa (human factor Xa labeled
in the active site with Oregon Green 488; [OG488]-EGRhXa). In contrast, peptide containing the sequence
327
AAEEV331 was found to interact with [OG488]-EGRhXa with half-maximal saturation reached at ⬃150 M,
but it was unable to produce a cofactor effect on factor
Xa. Peptide 325FIAAE329 inhibited prothrombinase activity and was able to partially decrease the fluorescent
anisotropy of [OG488]-EGR-hXa but could not increase
the catalytic efficiency of factor Xa with respect to prothrombin. A control peptide with the sequence FFFIA
did not increase the catalytic efficiency of factor Xa,
whereas a peptide with the sequence AAEMI was impaired in its capability to interact with [OG488]-EGRhXa. Two mutant recombinant factor Va molecules
(Glu323 3 Phe/Tyr324 3 Phe, factor VaFF; Glu330 3 Met/
Val331 3 Ile, factor VaMI) showed impaired cofactor activity when used at limiting cofactor concentration,
whereas the quadruple mutant (Glu323 3 Phe/Tyr324 3
Phe and Glu330 3 Met/Val331 3 Ile, factor VaFF/MI) had no
cofactor activity under similar experimental conditions.
Our data demonstrate that amino acid residues Glu323,
Tyr324, Glu330, and Val331 of factor Va heavy chain are
critical for expression of factor Va cofactor activity.

The maintenance of hemostasis is a complex event requiring
the controlled interaction of proteases, zymogens, cofactors,
and inhibitors on surfaces provided by platelets and endothelial cells, culminating in timely ␣-thrombin formation at the
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site of a vascular injury. The enzymatic complex prothrombinase, which activates prothrombin, is required for normal blood
clotting and is composed of the enzyme, factor Xa, and the
protein cofactor, factor Va, associated on a cell surface in the
presence of divalent metal ions (1, 2). Whereas factor Xa possesses the enzymatic capability to activate prothrombin, the
incorporation of factor Va into prothrombinase and its interaction with factor Xa increase the catalytic efficiency of the enzyme by 5 orders of magnitude as compared with factor Xa
alone (3). The increase in the catalytic efficiency of prothrombinase as compared with factor Xa alone is believed to arise
from a 100-fold decrease in the Km and a 3000-fold increase in
the kcat of the enzyme (4 –7). The decrease in the Km of the
reaction appears to be the result of the interaction of the
complex with the cell surface, resulting in higher local concentration of substrate. The increase in the kcat of prothrombinase
is attributed to the binding of factor Va to factor Xa. The bulk
of the data generated suggest that incorporation of factor Va
into prothrombinase and its interaction with factor Xa and
prothrombin do not have any significant effect on the catalytic
site of the enzyme (8 –10). The accumulated data suggest that
binding of factor Va to factor Xa induces a conformational
transition in the structure of the enzyme exposing a prothrombin-binding exosite on the enzyme, resulting in more efficient
catalysis. However, the cofactor itself may also represent a
portion of the exosite for prothrombin. Evidence for a direct
interaction of factor Va with prothrombin has been repetitively
provided (11–14). The amino acids responsible for this dual
effect of factor Va on factor Xa remain to be identified.
Human factor V circulates in plasma as a single chain glycoprotein of Mr 330,000 consisting of multiple domains A1-A2B-A3-C1-C2, at a concentration of ⬃20 nM (15–18). The factor V
gene is 80 kb in length and contains 24 introns, whereas the
mRNA is 6.9 kb long (19). Single chain factor V does not appear
to interact with factor Xa and to have cofactor activity. Factor
V is cleaved sequentially by ␣-thrombin at Arg709, Arg1018, and
Arg1545 to produce the active cofactor, factor Va, that consists of
a heavy chain (Mr 105,000) and a light chain (Mr 74,000). The
heavy chain derives from the NH2-terminal part of factor V
(A1-A2 domains, residues 1–709), whereas the light chain represents the COOH-terminal end of the procofactor (A3-C1-C2
domains, residues 1546 –2196) (17). The heavy and light chains
are noncovalently associated via divalent metal ions (20). Activation of the procofactor by ␣-thrombin is required for expression of its cofactor activity (i.e. interaction with factor Xa and
prothrombin). Both chains of the cofactor are required for the
high affinity interaction with factor Xa (21–23). The data accumulated thus far indicate that the binding of factor Va and/or
factor Xa to the lipid bilayer most likely results in conformational changes in one or both proteins that contribute to aspects
of the factor Va-factor Xa interaction. Factor Va and factor Xa
interact stoichiometrically in the presence and absence of phos-
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pholipids. In the absence of phospholipids, the Kd for the interaction is 0.8 M and is dependent upon the presence of Ca2⫹
ions (24). Upon binding of both proteins to lipids, the Kd of the
interaction decreases by ⬃1000-fold to 1 nM (4, 5), suggesting
that multiple points of contact between the two proteins are
exposed, resulting in the tighter interaction. Because of the
physiological concentration of the two proteins in plasma, the
only physiologically relevant Kd for the interaction between the
two proteins is the Kd observed in the presence of a membrane
surface. Factor Va is inactivated by activated protein C (APC),1
following cleavage at Arg506, Arg306, and Arg679 only in the
presence of a membrane surface (25, 26). Cleavage of factor Va
by APC at Arg506 results in a 10-fold decrease in the affinity of
the molecule for factor Xa and is required for efficient cleavage
at Arg306 (25–27). Subsequent cleavage at Arg306, which is
lipid-dependent and is the inactivating cleavage site, completely abolishes the ability of the cofactor to interact with
factor Xa because of the dissociation of the heavy chain fragments from the light chain, hence eliminating the factor Vafactor Xa interaction (27). Thus, whereas activation of factor V
by ␣-thrombin allows for proper interaction of factor Va with
factor Xa, APC inhibits this interaction by eliminating the
binding site(s) of the cofactor for the enzyme. These combined
data suggest that the regulation of normal hemostasis and
control of thrombosis is exerted following the activation and
inactivation processes of the cofactor, which ultimately and
explicitly control its interaction with factor Xa. As a consequence, a complete understanding of prothrombinase assembly
and function, which is a prototype for most membrane-bound
complexes contributing to the blood clotting processes, necessitates the identification of the distinct amino acids from each
protein responsible for their interaction as well as a complete
understanding of the macromolecular interactions that occur
between them.
We have shown that a synthetic peptide containing a sequence of amino acids from the middle portion of factor Va
heavy chain (amino acid residues 307–348; N42R) (every peptide is identified by the first and last amino acids, with the
number of residues composing the peptide in the middle) inhibits factor Va cofactor activity (28). We have recently demonstrated, using overlapping peptides, that a nonapeptide from
N42R containing amino acid sequence 323–331 of factor Va
(AP4⬘), is the active inhibitory portion of N42R and represents
a direct binding site for factor Xa (29). Both peptides, N42R and
AP4⬘, also produced a “cofactor” effect on factor Xa, increasing
the catalytic efficiency of the enzyme by 21- and 4-fold, respectively, as compared with factor Xa alone (29). The present
study was undertaken to identify the amino acid residues
within AP4⬘ that are responsible for its biological activities.
EXPERIMENTAL PROCEDURES

Materials, Reagents, and Proteins—Hepes, Trizma (Tris base), QSepharose fast flow, Sepharose CL-4B, bovine serum albumin, Coomassie Brilliant Blue R-250, diisopropyl fluorophosphate (DFP), o-phenylenediamine dihydrochloride (OPD), and factor V-deficient plasma
1
The abbreviations used are: APC, activated protein C; DFP, diisopropyl fluorophosphate; OPD, o-phenylenediamine dihydrochloride; PS,
L-␣-phosphatidylserine; PC, L-␣-phosphatidylcholine; PCPS, small
unilamellar phospholipids vesicles composed of 75% PC and 25% PS
(w/w); DAPA, dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide; EGRhXa, glutamylglycinylarginyl chloromethyl ketone active site-blocked
human factor Xa; [OG488]-EGR-hXa, human factor Xa labeled in the
active site with Oregon Green 488; PVDF, polyvinylidene difluoride;
ELISA, enzyme-linked immunosorbent assay(s); factor VaFF, recombinant human factor Va with the mutations Glu323 3 Phe/Tyr324 3 Phe;
factor VaMI, recombinant human factor Va with the mutations Glu330 3
Met/Val331 3 Ile; factor VaFF/MI, quadruple mutant, recombinant human factor Va with the mutations Glu323 3 Phe/Tyr324 3 Phe and
Glu330 3 Met/Val331 3 I; mOD, 10⫺3 OD.

were purchased from Sigma. Heparin-Sepharose and the chemiluminescent reagent ECL⫹ were from Amersham Biosciences. Anti-mouse
and anti-sheep IgG coupled to peroxidase were from Southern Biotechnology Associates Inc. (Birmingham, AL). L-␣-Phosphatidylserine (PS)
and L-␣-phosphatidylcholine (PC) where from Avanti Polar Lipids (Alabaster, AL). Normal reference plasma, the chromogenic substrate for
thrombin, Spectrozyme-TH, and hirudin were from American Diagnostica Inc. (Greenwich, CT). The thromboplastin reagent used in the
clotting assays was purchased from Organon Teknika Corp. (Durham,
NC). Polyethylene glycol (Mr 8000) was from J. T. Baker Inc. The
fluorescent thrombin inhibitor dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide (DAPA), human factor Xa, human ␣-thrombin, human
prothrombin, the monoclonal antibody ␣HFV 1 coupled to Sepharose,
D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone, EGR-hXa (glutamylglycinylarginyl chloromethyl ketone active site-blocked human
factor Xa), and human factor Xa labeled in the active site with Oregon
Green 488 ([OG488]-EGR-hXa), as previously described (30), were from
Hematologic Technologies Inc. (Essex Junction, VT). The cDNA for
factor V was purchased from American Type Tissue Collection (ATCC
number 40515 pMT2-V; American Type Culture Collection; Manassas,
VA). The sequence of this cDNA molecule is identical to the cDNA
published by Jenny et al. (17). All restriction enzymes were from New
England Biolabs (Beverly, MA), and all other molecular biology and
tissue culture reagents and media were from Invitrogen or as indicated.
The two monoclonal antibodies to human factor V (against the heavy
and light chains of the cofactor, i.e. ␣HFVHC 17 and ␣HFVLC 9) were
provided by Dr. Kenneth G. Mann (Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT). These antibodies have been thoroughly characterized (31–34). Overlapping peptides from the region 323–331 of factor V were synthesized in the
analytical facility of Dr. Satya Yadav at the Cleveland Clinic Foundation (Cleveland, OH), purified by high performance liquid chromatography, and characterized by mass spectrometry as described (29). Human factor V was purified as previously described using the monoclonal
antibody ␣HFV 1 coupled to Sepharose (35, 36). Factor Va was obtained
as recently described using heparin-Sepharose (29). Prior to use, factor
Va was concentrated using Centricon (Mr 30,000 cut-off YM-30; Millipore Corp., Bedford, MA) and stored on ice at 4 °C. Because of the
instability of the active cofactor following prolonged storage on ice at
4 °C, factor Va preparations were made as needed and in small quantities. The quality of each preparation was assessed prior to use by
measuring the activity of the factor Va molecule systematically by a
clotting assay using factor V-deficient plasma and standardized to the
percentage of control (35). Phospholipid vesicles composed of 75% PC
and 25% PS (referred to as PCPS vesicles throughout) were prepared as
previously described (37). The concentration of the phospholipid vesicles was determined by phosphorous assay as described (38) and is
given as the concentration of inorganic phosphate.
Assay Measuring Thrombin Formation—The formation of thrombin
was analyzed using the fluorescent thrombin inhibitor DAPA as described (25, 26, 29, 39) using a PerkinElmer LS-50B Luminescence
Spectrometer with ex ⫽ 280 nm, em ⫽ 550 nm, and a 500-nm-long pass
filter in the emission beam (Schott KV-500). The buffer used in all cases
was composed of 20 mM Hepes, 0.15 M NaCl, 5 mM CaCl2, pH 7.4
(HBS(Ca2⫹), “assay buffer”). The final concentration of factor Va in the
mixture was 4 nM, with factor Xa at 10 nM. Under these conditions, the
rate of thrombin formation is linearly related to the amount of active
cofactor (factor Va). The initial rate of thrombin formation (nM IIa/min)
was calculated as described (25, 26, 29). The concentration of peptide
given in each figure is the final concentration of the peptide in the assay
mixture. All data were initially analyzed and stored using the software
FL WinLab (PerkinElmer Life Sciences) provided by the manufacturer
and further analyzed and plotted with the software Prizm (GraphPad,
San Diego, CA).
Fluorescence Anisotropy Measurements—Fluorescence anisotropy of
[OG488]-EGR-hXa was measured using a PerkinElmer LS-50B Luminescence Spectrometer in L format as recently described (29). Anisotropy measurements were performed in a quartz cuvette under constant
stirring (low) with ex ⫽ 490 nm and em ⫽ 520 nm with a long pass
filter (Schott KV-520) in the emission beam. At each addition, anisotropy was measured for 20 s and averaging eight successive readings. In
all cases, the total addition of peptide did not exceed 10% of the volume
of the reaction. The concentration of peptide given in each graph is the
final concentration of the peptide in the assay mixture. All data were
initially analyzed and stored using the software FL WinLab
(PerkinElmer Life Sciences) and further analyzed and plotted with the
software Prizm (GraphPad). Some of the data were also plotted using
DeltaGraph (DeltaPoint, Monterey, CA).
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Mutagenesis and Transient Expression of Recombinant Factor V Molecules—The complete 6.909-kb-long cDNA sequence for factor V containing a leader sequence (from 91 to 174 bp) that encodes the signal
peptide was inserted into the mammalian expression vector pMT2 at
SalI sites. Mutant molecules were designed by keeping in mind that in
order to positively identify the amino acids responsible for the effector
and receptor properties of factor Va, we have to express recombinant
factor V molecules with these specific amino acids mutated in such a
manner that the entire conformation of the recombinant factor V molecules possesses a tertiary conformation as close as possible to the wild
type factor Va molecule. For these reasons, we have made three conservative and one nonconservative mutation. As conservative substitutions, phenylalanine was substituted for a tyrosine in order to test the
function of the hydroxyl present on the later amino acid. Methionine
has a similar core structure as glutamic acid; however, the carboxyl
group of the latter is replaced by a thioether group in the former.
Although valine and isoleucine are both hydrophobic in nature, the
structure of the side chain of the latter is significantly different from the
structure of the side chain of the former. Finally, we have previously
observed that the presence of a glutamic acid at position 323 was a
prerequisite for optimum inhibitory potential of AP4⬘ (29). We have
thus performed a nonconservative mutation by replacing the carboxyl
group of glutamic acid with a phenyl group found in phenylalanine to
eliminate any potential contribution of this hydrophilic amino acid to
the interaction with factor Xa. PCR-based site-directed mutagenesis
was used for constructing the factor V mutants (i.e. pMT2-FV (Glu323 3
Phe/Tyr324 3 Phe, factor VFF), pMT2-FV (Glu330 3 Met/Val331 3 Ile,
factor VMI), and pMT2-FV (Glu323 3 Phe, Tyr324 3 Phe, Glu330 3 Met,
Val331 3 Ile, factor ValFF/MI)). The mutagenic primers for the mutant
Glu323 3 Phe/Tyr324 3 Phe were 5⬘-GAAGAGGTGGTTCTTCTTCATTGCTGC-3⬘ (sense) and 5⬘-GCAGCAATGAAGAAGGAACCACCTCTTC-3⬘ (antisense), whereas for the mutant Glu330 3 Met/Val331 3 Ile the
primers were 5⬘-CATTGCTGCAGAGATGATCATTTGGGACTATGC-3⬘
(sense) and 5⬘-GCATAGTCCCAAATGATCATCTCTGCAGCAATG-3⬘
(antisense) (underlined letters indicate the mismatch). The outer PCR
primers were 5⬘-ACATCCACTACCGCAATATGAC-3⬘ (sense) and 5⬘CCTCAGGCAGGAACAACACCATGA-3⬘ (antisense), corresponding to
nucleotide positions 964 –979 (upstream of a XcmI restriction site) and
1481–1504 (downstream of a Bsu361 site), respectively (according to
Jenny et al. (17); GenBankTM accession number M16967). Each sitedirected mutagenesis was carried out by three-step PCRs. The first two
PCRs were performed using the sense outer primer and antisense
mutagenic primers or antisense outer primer and sense mutagenic
primers. The complete DNA fragment removed from the pTM2-FV wild
type sequence by digesting with SalI was used as a template for the
PCR. The third reaction was performed using outer sense and antisense
primers and the purified PCR products of the first two reactions as
templates. All PCRs were performed with high fidelity Taq polymerase.
PCRs were programmed as follows: denaturation at 94 °C for 15 s,
annealing at 55 °C for 30 s, and extension at 68 °C for 1 min/kb in a
GeneAmp PCR system 9700 DNA thermal cycler (PerkinElmer Life
Sciences). The amplicons of each third reaction were ligated into the
cloning plasmid vector pGEM-T, and the integrity of the constructs was
verified following sequencing using an ABI Prism automatic DNA sequencer and the universal primers T7 and SP6 as well as other factor V
sequence-specific primers as needed at the sequencing facility at the
Cleveland Clinic Foundation. The quadruple mutant pMT2-FV (E323F/
Y324F/E330M/V331I) was made using the pGEM-T plasmid vector
containing the DNA insert of factor VFF as template and the mutagenic
primers used for factor VMI. The inserts (nucleotides 964 –1504) were
removed from the pGEMT-FV plasmid constructs (mutant fragments)
following digestion with XcmI and Bsu361 restriction enzymes. Following purification of the inserts from the agarose gel, the factor V inserts
that possess the mutations (nucleotide positions 964 –1504) were religated into pMT2-FV, in which the DNA fragment between the XcmI and
Bsu361 restriction sites was removed. The ligated plasmids were transformed into JM109 bacterial competent cells. Positive ampicillin-resistant clones for pMT2-FV mutants were selected. The correct sequences
and orientations of the inserts were established by DNA sequence
analysis with factor V-specific primers. The wild-type pMT2-FV and
mutant pMT2-FV plasmids were isolated from the bacterial culture by
the QIAfilter plasmid Midi kit (Qiagen Inc., Valencia, CA).
Recombinant Factor V-Wild Type and Factor V Mutant Transfection
into COS-7 Cells—COS-7 cells (ATTC) or COS-7L, (Invitrogen) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum, 2 mM L-glutamine, and antibiotics (100 g/ml
streptomycin and 100 IU/ml penicillin) in a humidified atmosphere of
5% CO2 and 95% air at 37 °C. The purified plasmids pMT2-FV wild
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type, pMT2-FV(E323F/Y324F), pMT2-FV(E330M/V331I), and pMT2FV(E323F/Y324F/E330M/V331I) were used to transfect into COS-7/
COS-7L cells as follows. Each plasmid (1–2 g) was transfected into
50 – 80% confluent COS-7/COS-7L cells in a 100-mm culture plate using
lipid-based transfection reagent FUGENE 6 (Roche Diagnostics) according to the manufacturer’s instructions. Following 48 h of transfection, the medium was removed. Cells were washed twice with serumfree medium, and 6 –10 ml of conditioned medium VP-SFM
supplemented with 4 mM of L-glutamine was added. After growing the
cells in the conditioned medium for 24 h, medium was harvested, and
6 –10 ml of fresh condition medium was added. After growing the cells
for another 24 h, the media were harvested again. The harvested
medium containing recombinant factor V was briefly centrifuged at
4,500 rpm at 4 °C to remove insoluble particles. All control media and
solutions containing the recombinant factor V molecules were concentrated using centrifugal ultrafiltration (Centricon YM 30,000; Millipore
Corp.), washed with 20 mM Tris, 0.15 M NaCl, 5 mM CaCl2, pH 7.4,
following repeated concentration steps, and stored on ice at 4 °C. The
activity and the integrity of the molecules were verified before and after
thrombin activation by clotting assays using factor V-deficient plasma
and by Western blotting using the appropriate monoclonal and polyclonal antibodies. The recombinant molecules were stable under these
conditions for at least 1 week. The concentrations of the recombinant
molecules were determined by an ELISA developed in our laboratory
and described below. The values found in our ELISA were similar to the
concentration of recombinant factor V determined using the commercially available factor V ELISA kit (Affinity Biologicals, Hamilton,
Ontario, Canada). It is noteworthy that in all experiments performed
herein, before concentration of the recombinant molecules, the double
mutant (factor VFF/MI) was found to be consistently secreted in lower
concentrations than the wild type procofactor molecule or the single
mutants (i.e. the mutants with only two amino acids mutated at the
time, factor VFF or factor VMI). However, its concentration was normalized and adjusted in all prothrombinase assays. Thus, all recombinant
molecules were assayed under similar experimental conditions.
Determination of the Concentration of the Recombinant Factor V
Molecules—The concentration of factor V was determined with an
ELISA. 20 l of polyclonal anti-human factor V (10 mg/ml) was diluted
into 20 ml of coating buffer (0.077 M NaHCO3, 0.007 M Na2CO3, pH 9.5).
A 96-well microtiter plate (Costar, Corning Glass) was loaded with 200
l/well of the polyclonal antibody mixture and incubated overnight at
4 °C. The final concentration of the antibody in each well was 10 g/ml.
The plate was washed three times with 25 mM Tris, 0.15 M NaCl, pH
7.4, 0.05% Tween 20 (TBS-Tween, washing buffer), following by incubation with 100 l/well of 5% nonfat dry milk in TBS-Tween at 37 °C for
1 h. Following extensive washing, the plate was loaded (100 l/well)
with either serial dilutions of purified plasma factor V in VP-SFM
medium with 4 mM L-glutamine within the range of 20 g to 5 ng of
factor V in triplicate or with various volumes of recombinant factor V
solutions in triplicate. Normal plasma factor V was diluted in the
medium in order to rule out the possibility that the cell culture media
would interfere with the ELISA assay. Following incubation at 37 °C for
1 h, the plate was washed three times followed by incubation with
␣HFVHC 17 at 5 g/ml final concentration (per well) for 1 h at 37 °C.
Following extensive washing, a 1:2000 dilution of goat anti-mouse antibody coupled to peroxidase was loaded on the wells (100 l/well), and
incubation was allowed to proceed at 37 °C for an additional 1 h. The
plates were developed with OPD tablets (5 mg), which were dissolved in
0.1 M citric acid, 0.1 M Na2HPO4 (12 ml). Immediately prior to use, 12 l
of 30% H2O2 was added to the OPD solution (developing solution), and
100 l was applied per well. Following incubation at room temperature,
the reaction was stopped with 150 l of 1.5 M H2SO4. The absorbance at
490 nm was monitored using an Amersham Biosciences THERMOMAX
microplate reader. Because of slight differences in time of incubation
with the substrate, in every experiment a plasma factor V standard
(serial dilutions of purified plasma factor V) was run, and all values
obtained with the recombinant molecules were compared with the
plasma factor V standard values within the same 96-well plate. No
comparison in concentration was made between recombinant molecules
from one plate and the other. The determination of the concentration of
the recombinant molecules was performed by averaging the value found
for each sample run in triplicate.
Measurement of Rates of ␣-Thrombin Formation in a Prothrombinase
Assay—Since even after concentration, the recombinant molecules resulting from the transient expression were obtained in limited
amounts, cofactor activity measurements using DAPA were not possible. The activity of all recombinant factor V molecules was thus measured in a discontinuous assay as follows. All factor V species were
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activated with 10 nM thrombin for 20 min followed by the addition of
DFP (5 mM). The factor Va solution was then incubated for an additional 30 min on ice. Control experiments demonstrated that under
these conditions, no interference of the DFP with the assay could be
observed, since DFP is readily hydrolyzed in aqueous solution. Assay
mixtures contained PCPS vesicles (20 M), DAPA (3 M), various recombinant factor Va species (0.5 nM), and prothrombin (1.4 M) in 20
mM HEPES, 0.15 M NaCl, 5 mM CaCl2, pH 7.4. The mixture was allowed
to incubate at ambient temperature for 5 min, and the reaction was
initiated by the addition of factor Xa (5 nM). Aliquots of the reaction
mixture were removed at various time intervals, as indicated in the
figures, and diluted 3-fold in 20 mM HEPES, 0.15 M NaCl, 50 mM EDTA,
0.1% polyethylene glycol 8000, pH 7.4, in a 96-well microtiter plate
(Costar, Corning Glass) to quench the reaction. The formation of
␣-thrombin in each sample was monitored using the chromogenic substrate Spectrozyme TH (0.4 mM, final concentration). The change in the
absorbance at 405 nm was monitored using the Amersham Biosciences
THERMOMAX microplate reader. The initial rate of ␣-thrombin generation under these conditions is linear, and in all experiments no more
than 10% of prothrombin was consumed during the initial course of the
assay. An excess of the specific ␣-thrombin inhibitor DAPA was included in all experiments to prevent potential feedback reactions catalyzed by ␣-thrombin that is generated during the assay. All data were
analyzed with the software Prizm (GraphPad). Some of the data were
also plotted using DeltaGraph (DeltaPoint).
Gel Electrophoresis and Western Blotting—SDS-PAGE analyses were
performed using 5–15% gradient gels according to the method of Laemmli (40). When necessary, proteins were visualized after staining with
Coomassie Brilliant Blue. In several experiments, proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore Corp.)
according to the method described by Towbin et al. (41). After transfer
to nitrocellulose, factor V heavy and light chain(s) were detected using
the appropriate monoclonal and polyclonal antibodies (31–34). Immunoreactive fragments were visualized with chemiluminescence.
Analysis of the Inactivation of Membrane-bound Factor Va (with or
without EGR-hXa)—The inactivation of factor Va by APC was studied
in the presence or absence of synthetic peptides. EGR-hXa was preincubated with peptides and added to purified membrane-bound factor
Va. The final concentrations of all reagents were as follows: factor Va,
20 nM; EGR-hXa, 50 nM; PCPS vesicles, 5 M; pentapeptides, 200 M;
AP4⬘, 8 M; A9A, 8 M. The reaction was initiated by the addition of
APC (5 nM). Samples of the mixture were withdrawn at selected time
intervals (indicated in the legends to the figures), mixed with 2% SDS,
and heated for 5 min at 90 °C prior to analysis by gel electrophoresis.
Following transfer to PVDF membranes, factor Va-immunoreactive
fragments were visualized with monoclonal antibody ␣HVaHC 17
and chemiluminescence.
RESULTS

Inhibition of Prothrombinase Assembly and Function by Synthetic Peptides from the Region 323–331 of Factor Va Heavy
Chain—We have recently shown that a 9-amino acid peptide
containing the region 323–331 of factor Va heavy (AP4⬘)
chain inhibits factor Va cofactor activity in a noncompetitive
manner with respect to substrate (prothrombin) with a Ki of
5.7 M (29). We have also shown that binding of factor Va and
AP4⬘ to factor Xa are mutually exclusive (29). In order to
differentiate between the amino acids of the nonapeptide that
are important for its functions, we synthesized three overlapping peptides, of five amino acids each, spanning the
323–331 region (Fig. 1A). Each pentapeptide, except the first
and the last, has 3 amino acids in common with the preceding
and the following peptide of the series (Fig. 1A). Thus, the
first peptide (E5A) has its first 2 amino acids that are unique
to its sequence, whereas the third peptide (A5V) has its last
2 amino acids unique to its sequence. We have also synthesized and tested two control pentapeptides that are mutated
at the extremities of AP4⬘ (Fig. 1B). Control peptides were
designed by keeping in mind that in order to positively identify the amino acids responsible for the effector and receptor
properties of factor Va, we will ultimately have to express
recombinant factor V molecules with these specific amino
acids mutated in such a manner that the entire conformation
of the recombinant factor V molecules possesses a tertiary

FIG. 1. Peptides from amino acid region 323–331 of factor V. A,
overlapping peptides (5 amino acids each) from the region 323–331 of
factor V. Every peptide is identified by the first and last amino acids,
with the number of residues composing the peptide in the middle. For
ease of reading of this report and the explicit identification of every
amino acid identified in our work, Glu323 and Val331 are identified as
the beginning and the end of the sequence of interest. B, control peptides used in the study. The changed amino acids are in boldface type
and underlined. F5A is the control peptide for E5A, whereas A5I is the
control peptide for A5V.

conformation as close as possible to the wild type factor Va
molecule (see below).
These peptides were first assayed for inhibition of prothrombinase function. Under the conditions employed, all three peptides showed various degrees of inhibition, with E5A being
more potent at low concentrations, whereas A5V was more
potent at high concentrations of peptide (Fig. 2, dark filled
bars). Thus, as previously suggested, the pentapeptides contain
amino acids that all appear to contribute to the inhibitory
potential of AP4⬘ (29). Experiments using the control peptides
demonstrated that replacing Glu323 and Tyr324 by 2 phenylalanines resulted in diminished inhibitory potential of F5A (Fig. 2,
hatched bars, 100 and 300 M), whereas replacing Glu330 and
Val331 by methionine and isoleucine, respectively, resulted in a
diminished inhibitory potential of A5I (Fig. 2, hatched bar, 500
M). However, both control peptides had an inhibitory effect on
prothrombinase, albeit less potent than their parent peptides.
The open bars in Fig. 2 depict the positive and negative control
peptides AP4⬘ and A9A previously characterized (29).
We have shown that AP4⬘ interacts with [OG488]-EGR-hXa
with half-maximal saturation of ⬃65 M (29). We have thus
tested the three pentapeptides for their ability to interfere with
the fluorescence anisotropy of membrane-bound [OG488]-EGRhXa in the absence of factor Va (Fig. 3). The data show that
increasing concentrations of A5V produce a significant decrease (quench) in the fluorescent anisotropy of [OG488]-EGRhXa (Fig. 3, filled inverted triangles), demonstrating direct
interaction between the peptide and [OG488]-EGR-hXa. Halfmaximal saturation was reached at ⬃150 M peptide. A control
pentadecapeptide (P15H) previously shown to have no effect on
prothrombinase assembly and function (29) produced a ⬃20%
decrease in the anisotropy of [OG488]-EGR-hXa when used at
300 M (not shown). Peptide E5A had a similar effect on the
anisotropy of [OG488]-EGR-hXa (⬃22% decrease in the anisotropy, assuming that the decrease observed in the presence of
A5V is the maximum possible effect) (Fig. 3, filled diamonds).
Under similar experimental conditions, and in the presence of
400 M peptide F5E, there was a 42% decrease in the anisotropy of [OG488]-EGR-hXa (Fig. 3, filled triangles). This effect of
F5E remained constant even at concentrations as high as 700
M peptide. The data indicate that A5V alone appears to contain most of the amino acids that are responsible for the direct
interaction between [OG488]-EGR-hXa and AP4⬘. However, an
additional contribution of 3 amino acids common to F5E and
A5V is also apparent. No significant effect of the control peptide A5I was observed on the fluorescent anisotropy of [OG488]EGR-hXa (the decrease in the anisotropy observed was similar
to that of a control peptide inducing ⬃20% change in the
fluorescent anisotropy) (Fig. 3, filled squares). Overall, these
data point to two amino acids, Glu330 and Val331, within the
sequence of AP4⬘ that appear to be largely responsible for the
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FIG. 2. Inhibition of prothrombinase function by synthetic
overlapping peptides from AP4ⴕ. Peptides were incubated with factor Xa as detailed under “Experimental Procedures” at a fixed concentration (shown at the bottom of each histogram). The final concentration
of factor Xa in the mixture was 10 nM (with human factor Va at 4 nM).
The percentage of factor Va cofactor activity was calculated by comparing the activity of prothrombinase in the presence of a given peptide
(the rate of thrombin formation) with the activity of prothrombinase
determined in a control reaction in the absence of peptide and in the
presence of factor Xa. The amino acid sequence and identification of
each peptide are given in Fig. 1. The data represent the average of the
results found in three independent measurements. The identity of the
peptide used in each group of measurements is given at the bottom.
Filled bars, pentapeptides from AP4⬘; hatched bars, control peptides;
open bars, controls for the entire experiment.

FIG. 3. Direct interaction with of [OG488]-EGR-hXa. [OG488]EGR-hXa (10 nM) in the presence of PCPS vesicles (10 M) but in the
absence of factor Va was titrated with increasing concentrations of E5A
(filled diamonds), F5E (filled triangles), A5V (filled inverted triangles),
and A5I (filled squares) as previously described (29) and briefly detailed
under “Experimental Procedures.” Fluorescence anisotropy was measured at 25 °C, and the ⌬r was calculated as previously described (29, 30)
and detailed under “Experimental Procedures.”

decrease of the anisotropy of [OG488]-EGR-hXa when incubated
with the peptide. It is noteworthy that since all three peptides
inhibit prothrombinase, they most likely interact with factor
Xa; however, only A5V appears to contain amino acids capable
of producing a significant decrease of the fluorescent anisotropy of [OG488]-EGR-hXa.
High concentrations of AP4⬘ and N42R were shown to have a
cofactor effect on factor Xa (29). To understand which amino
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FIG. 4. Cleavage of factor Va by APC in the presence of active
site blocked factor Xa. Factor Va (40 nM) was cleaved by APC (5 nM)
in the absence (A) or presence (B) of EGR-hXa (80 nM) and PCPS.
Samples were analyzed on 5–15% linear gradient SDS-PAGE gels.
Following transfer to PVDF membranes, fragments were detected using
monoclonal antibody ␣HFVaHC 17. Lane 1, membrane-bound factor Va;
lanes 2– 8, factor Va at 1, 3, 5, 8, 10, 15, and 30 min following the
addition of APC. The positions of molecular weight markers are indicated at the left, whereas the positions of the factor Va fragments
recognized by the monoclonal antibody are indicated at right. In parentheses, under the identification of each fragment, the amino acid sequence of each fragment is also given.

acids from AP4⬘ are responsible for this effect, we assayed the
pentapeptides for their ability to increase the catalytic efficiency of factor Xa during activation of prothrombin in the
absence of factor Va. Incubation of E5A (100 M) with factor Xa
resulted in a modest but significant and reproducible increase
of the activity of factor Xa with respect to prothrombin activation (⬃150%) when compared with the activity of factor Xa
alone (not shown). No increase in the activity of factor Xa was
observed in the presence of any of the other peptides shown in
Fig. 1. Thus, amino acids Glu323 and Tyr324 may be responsible for the cofactor effect of AP4⬘ on factor Xa (29). Overall,
these data demonstrate that Glu323, Tyr324, Glu330, and
Val331, which represent amino acids located at the extremities of AP4⬘, are crucial for the inhibitory potential of the
peptide on both prothrombinase assembly and function.
These amino acids may be thus required for expression of
factor Va cofactor function.
Elimination of the Protective Effect of Factor Xa during
Membrane-dependent Inactivation of Factor Va by APC—It has
been established that factor Xa protects factor Va from inactivation by APC (42– 44). APC inactivation of factor Va following
cleavage of the membrane-bound cofactor at Arg506/Arg306 and
generation of the Mr 30,000 fragment (containing amino acid
residues 307–506) is fast and occurs within 1 min (Fig. 4A) (26).
Following preincubation of the cofactor with EGR-hXa, the
appearance of the Mr 30,000 fragment of factor Va is considerably delayed (Fig. 5B, lanes 2– 8), and an increase in the concentration of an Mr 60,000/54,000 doublet is observed (Fig. 4B,
lanes 2– 6). This doublet represents initial cleavage of the cofactor at Arg306 (26, 31). Our data are in agreement with a
previous report showing that upon incubation of the membrane-bound cofactor with EGR-hXa, the rate of cleavage at
Arg506 is considerably impaired (44). Altogether, these data
suggest that upon interaction with the membrane-bound cofactor, the EGR-hXa molecule impairs cleavage by APC at Arg506
by hindering access of APC to specific amino acids that are
required for its interaction with factor Va and subsequent
catalysis. Thus, by preincubating the cofactor with EGR-hXa,
we are creating an artificial and transient factor VLEIDEN molecule (31). However, since the factor Va molecule still possesses
an arginine at position 506, inactivation of the molecule will
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FIG. 5. Competition for factor Va binding. Factor Va was incubated with PCPS vesicles. In a different reaction tube, EGR-hXa was incubated
with various synthetic peptides. The final concentration of EGR-hXa and the concentration of each peptide are given under “Experimental
Procedures.” The EGR-hXa molecule, which was preincubated with the peptides, was added to the membrane-bound factor Va solution. APC was
then added, and aliquots were withdrawn at selected time intervals and analyzed on 5–15% linear gradient SDS-PAGE gels. Following transfer
to PVDF membranes, fragments were visualized using monoclonal antibody ␣HFVaHC 17. Lane 1, membrane-bound factor Va, no APC; lanes 2– 6,
factor Va at 1, 3, 5, 8, and 10 min following the addition of APC. A, EGR-hXa preincubated with AP4⬘; B, EGR-hXa preincubated with A9A; C,
EGR-hXa preincubated with E5A; D, EGR-hXa preincubated with F5E; E, EGR-hXa preincubated with A5V; F, EGR-hXa preincubated with A5I;
G, EGR-hXa preincubated with F5A. Molecular weight markers are indicated at the left of A.

still proceed but with the order of cleavages reversed; the first
cleavage at Arg306 will be followed by a slow cleavage at Arg506
and generation of the Mr 30,000 fragment. As a consequence,
the appearance of the Mr 30,000 will be delayed, whereas the
Mr 60/54,000 doublet will be more pronounced compared with
the cleavage of factor Va in the absence of EGR-hXa (Fig. 4B,
lanes 2– 8). These data verify the crucial importance of prior
cleavage at Arg506 for cleavage at Arg306 and rapid inactivation
of the cofactor as previously suggested (26, 31, 32). These data
also demonstrate that we can distinguish between the binding
of EGR-hXa to the membrane-bound cofactor or not by the
absence or presence, respectively, of the Mr 30,000 fragment (at
the beginning of the reaction). Our previous (29) and present
data show that a factor Xa binding site is contained within
amino acid residues 323–331 of factor Va heavy chain. Thus,
we can formulate the hypothesis that upon preincubation of
EGR-hXa with a peptide from factor Va that contains a binding
site for factor Xa, binding to the cofactor will be prevented,
resulting in the elimination of the protective effect of EGR-hXa
from APC inactivation. As a consequence, membrane-bound
factor Va will be rapidly cleaved by APC with the appearance of
the Mr 30,000 fragment. The data resulting from such an
experiment are illustrated in Fig. 5. To simplify the figure and
for the easy analysis of the data, we have focused on the portion
of the gels around the region showing the Mr 30,000 fragment
resulting from cleavage of factor Va heavy chain at Arg506/
Arg306. The data only show the progress of the reaction through
the first 10 min.
Under the conditions employed, upon preincubation of EGRhXa with AP4⬘, inactivation of membrane-bound factor Va by
APC occurred normally with rapid cleavages at Arg506/Arg306
and appearance of the Mr 30,000 fragment (Fig. 5A). The appearance of the Mr 30,000 fragment was not observed when
EGR-hXa was preincubated with A9A, a peptide containing a
scrambled version of AP4⬘ (29) (Fig. 5B), demonstrating that 1)
AP4⬘ inhibits the interaction of EGR-hXa with membranebound factor Va, and thus, allows APC cleavage of the cofactor,
and 2) A9A, which does not interact with factor Xa, allows
protection of the membrane-bound cofactor by EGR-hXa from
cleavage by APC. Preincubation of EGR-hXa with either E5A
or A5V results in the appearance of the Mr 30,000 fragment
following incubation of the membrane-bound cofactor with APC
(Fig. 5, C and E). These data strongly suggest that the two
pentapeptides contain amino acids capable of interfering with
the binding of EGR-hXa to membrane-bound factor Va, thus
inhibiting the protective effect of the cofactor by EGR-hXa and
allowing APC cleavage of the heavy chain at Arg506/Arg306,

resulting in formation of the Mr 30,000 fragment. Consistent
with the findings shown in Figs. 2 and 3, the control peptides,
A5I (Fig. 5F) and F5A (Fig. 5G), did not interfere with the
ability of EGR-hXa to protect membrane-bound factor Va from
inactivation by APC. Interestingly, pentapeptide F5E, which
inhibited prothrombinase function and induced a modest decrease in the fluorescent anisotropy of [OG488]-EGR-hXa, was
unable to inhibit EGR-hXa protection of factor Va under the
conditions employed (Fig. 5D). Overall, these data confirm our
previous findings and demonstrate that peptides E5A and A5V
contain specific amino acids that are involved in their direct
interaction with factor Xa. It is noteworthy that in control
experiments, a delay in factor Va inactivation (a decrease in the
rate of appearance of the Mr 30,000 fragment) was observed
when APC was preincubated with high concentrations of AP4⬘
prior to the addition to the purified membrane-bound factor Va
molecule in the absence of EGR-hXa. The bulk of data thus far
accumulated demonstrate that amino acids Glu323, Tyr324,
Glu330, and Val331 of factor Va heavy chain, which are located
at the extremities of AP4⬘, are crucial for the interaction of the
cofactor with factor Xa.
Expression and Activation of Recombinant Human Factor
Va—In view of the data shown above, we used recombinant
technology to assess the effect of these 4 amino acids residues
on factor Va cofactor function. Three recombinant factor V
molecules were made: factor VFF and factor V with the mutations Glu323 3 Phe/Tyr324 3 Phe, factor VMI and factor V with
the mutations Glu330 3 Met/Val331 3 Ile, and factor VFF/MI
and factor V with four substitutions Glu323 3 Phe, Tyr324 3
Phe, Glu330 3 Met, and Val331 3 Ile. All recombinant molecules were expressed in COS-7L cells. The concentration of
each molecule prior to all assays was calculated using an
ELISA recently developed in our laboratory. The capture antibody was a polyclonal antibody (sheep anti-factor V), whereas
the detecting antibody was the monoclonal antibody ␣HFVHC
17 (31–34). For comparison, we have also used a commercially
available kit containing two polyclonal antibodies, previously
employed by other investigators, to assess the concentration of
recombinant factor V in conditioned media (45– 48). A linear
correlation between the absorbance at 490 nm and increasing
concentrations of purified plasma factor V was observed between 10 ng and 10 g of plasma factor V in both our assay and
the commercial ELISA kit (not shown). Further, all plasma and
recombinant molecules gave similar results in the two ELISA
(i.e. similar absorbance values at 490 nm were observed for a
given volume containing a recombinant molecule); thus, all
molecules were recognized with similar affinities by the detect-
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FIG. 6. Electrophoretic analyses of recombinant factor V molecules. Recombinant factor V molecules were activated by thrombin as
described under “Experimental Procedures” and analyzed on 5–15%
linear gradient SDS-PAGE. Following transfer to PVDF membranes,
the heavy chain and light chain of the recombinant molecules were
detected using a mixture of monoclonal antibodies ␣HFVaHC 17 (recognizing the heavy chain) and ␣HFVaLC 9 (recognizing the light chain).
Lane 1, plasma factor Va; lane 2, media harvested from cells without
the factor V construct (mock-transfected cells); lane 3, wild type recombinant factor Va; lane 4, factor VaFF; lane 5, factor VaMI; lane 6, factor
VaFF/MI. The positions of the molecular weight markers are indicated at
the left. On the right, the positions of the heavy and light chains of
factor Va are shown. The open arrowhead identifies a degradation
product from factor Va that is recognized by the monoclonal antibody
directed to the light chain of the cofactor.

ing antibodies. The concentrations of the recombinant molecules in the media before concentration, using centrifugal ultrafiltration, varied from 300 ng/ml to 3.2 g/ml. Fig. 6 shows
an SDS-PAGE of the secreted molecules used in our experiments following concentration and incubation with ␣-thrombin. Fig. 6, lane 1, is a control sample representing the heavy
and light chains of plasma factor Va and demonstrates that all
heavy and light chains of the recombinant factor Va molecules
(wild type or mutated) (Fig. 6, lanes 3– 6) have similar molecular weights, which do not appear to be significantly different
from the molecular weight of the heavy and light chain(s) of the
plasma-derived factor Va molecule (Fig. 6, lane 1). Thus, introduction of the mutations in factor Va heavy chain does not alter
the ability of the recombinant molecules to be recognized by the
monoclonal antibodies; nor does it alter their mobility on an
SDS-PAGE. In Fig. 6, lane 2, a control sample is shown where
all steps were carried out with cells that do not contain the
cDNA for factor V (mock transfection). The open arrow identifies a Mr 50,000 fragment that is recognized by the monoclonal
antibody to the light chain of the cofactor. This band is present
in the plasma-derived cofactor molecule (visible upon prolonged exposure of the autoradiogram) and is also recognized
by a polyclonal antibody to human factor V. Overall, the data
demonstrate that the quality of the recombinant molecules is
similar to the quality of plasma-derived factor Va.
Functional Characterization of the Recombinant Molecules—
The recombinant molecules were first screened for clotting
activity in a one- and two-stage clotting assay (35). Whereas
factor VFF and factor VMI had ⬃10-fold less clotting activity
than the wild type recombinant factor Va molecule, the double mutant (factor VaFF/MI) was unable to promote clotting
under the conditions employed in a one- or two-stage clotting
assay using factor V-deficient plasma (i.e. the clotting activity of the double mutant was similar to the clotting activity
observed when using the concentrated media obtained from
mock-transfected COS-7L cells; not shown). Thus, whereas
mutation of 2 amino acids at the time results in a cofactor
with impaired clotting activity, substitution of all 4 amino
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FIG. 7. Comparison of the cofactor activities of the recombinant factor Va molecules. The cofactor activities of the various factor
Va molecules were measured following activation by thrombin in an
assay system using purified reagents and employing spectrozyme-TH to
probe for thrombin generation as described under “Experimental Procedures.” Initial rates of prothrombin activation were determined at
ambient temperature using 500 pM factor Va and 5 nM factor Xa. The
various factor Va species are depicted as follows. Filled circles, wild type
recombinant factor Va; open circles, plasma-derived factor Va; filled
inverse triangles, factor VaFF; filled triangles, factor VaMI; open squares,
factor VaFF/MI at 1 nM; open triangles, factor VaFF/MI at 2 nM; open
inverted triangles, factor VaFF/MI at 5 nM; open diamonds, factor Xa
alone, no factor Va; stars, factor Xa in the presence of media harvested
from control cells without the factor Va construct. The data represent
the average of the results found in three independent experiments.

acid residues resulted in the elimination of factor Va clotting
activity. These data suggest that these 4 amino acids are of
crucial importance for the expression of factor Va clotting
activity.
We next investigated the ability of the thrombin-activated
recombinant molecules (at 0.5 nM) to interact with factor Xa (5
nM) and be assembled into prothrombinase using an assay
employing purified reagents and a chromogenic substrate.
Since the assay is conducted with limiting cofactor concentrations, any dearth in cofactor activity may be explained by the
inability of the recombinant molecules to act as a cofactor for
factor Xa. The data demonstrated that under the conditions
employed wild type recombinant factor Va (Fig. 7, filled circles)
displayed similar cofactor activity as plasma-derived factor Va
(Fig. 7, open circles), 2550 and 2100 mOD/min, respectively.
Under similar experimental conditions, factor VaFF (Fig. 7,
filled inverted triangles) and factor VaMI (Fig. 7, filled triangles) showed decreased cofactor activities, of 450 and 150 mOD/
min, respectively. Thus, the activity of the two mutants is 5.7and 17-fold less compared with wild-type factor Va. However,
the activity of factor VaMI was ⬃3-fold lower than the activity
of factor VaFF and was always consistently lower than factor
VaFF in several other experiments using various concentrations of factor Xa.
In preliminary experiments, using several preparations of
the double mutant (factor VaFF/MI), we have observed that the
rate of thrombin generation by this mutant, under the conditions employed above (0.5 nM factor Va with 5 nM factor Xa),
could not be distinguished from the rate of thrombin generation
by factor Xa alone (Fig. 7, open diamonds, ⬃32 mOD/min) or
from the rate of thrombin generation by factor Xa in the presence of the media collected from mock-transfected cells (Fig. 7,
stars, 36 mOD/min). We have thus decided to measure thrombin generation by prothrombinase in the presence of increasing
concentrations of factor VaFF/MI (Fig. 7, 1 nM (open squares), 2
nM (open triangles), and 5 nM (open inverted triangles) with
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FIG. 8. Contribution of the light chain of factor Va to the
binding to factor Xa. The cofactor activities of the various factor Va
molecules were measured following activation by thrombin in an assay
system using purified reagents and employing Spectrozyme-TH to
probe for thrombin generation. Initial rates of prothrombin activation
were determined at ambient temperature using 5 nM factor Xa and
factor Va species as indicated under “Experimental Procedures.” The
various factor Va species are depicted as follows. Filled squares, wild
type factor Va (1 nM); filled circles, factor VaFF (1 nM); filled diamonds,
factor VaMI (1 nM); filled triangles, factor VaFF/MI at 10 nM. The data
represent the average of the results found in three independent
experiments.

factor Xa constant at 5 nM. The data obtained showed a small
but significant increase in the catalytic efficiency of factor Xa in
the presence of increasing concentrations of the double mutant,
up to 90 mOD/s in the presence of 5 nM factor VaFF/MI. A direct
comparison between wild type factor Va and the double mutant
revealed a 284-fold decrease in cofactor activity of factor
VaFF/MI (5100 mOD䡠min⫺1䡠nM⫺1 for the wild type and 18
mOD䡠min⫺1䡠nM⫺1 for factor VaFF/MI). These data demonstrate
that even in the presence of stoichiometric concentrations (Fig.
7, open inverted triangles) factor VaFF/MI is a poor cofactor for
factor Xa.
It has been established that binding sites from both chains of
the cofactor contribute to the interaction of the cofactor with
factor Xa (11, 21–24). In the experiment shown in Fig. 7, we
have assessed the contribution of factor Va to prothrombinase
at limited cofactor concentration. The experimental conditions
were thus designed to make prothrombinase assembly sensitive to any alterations in the factor Va molecule. However, if
the binding site from the light chain depends on the binding of
the heavy chain, by increasing the concentration of the cofactor
molecule (with factor Xa kept constant at 5 nM) we do not
expect to observe an increase in the rate of thrombin generation when using the mutant molecules. In contrast, if the binding site on the light chain can increase the catalytic efficiency
of factor Xa, independently of the binding site located on the
heavy chain, by increasing the concentration of the cofactor, an
increase in the catalytic efficiency of all mutants will
be observed.
A direct comparison between factor VaFF and factor VaMI (1
nM mutant cofactor with 5 nM factor Xa) demonstrated that the
activity of factor VaFF was 780 mOD/min, whereas the activity
of factor VaMI was 200 mOD/min (Fig. 8, filled circles and filled
diamonds, respectively). These data, together with the data
shown in Fig. 7, verify our previous conclusion that under
similar experimental conditions, the absence of amino acids
Glu330 and Val331 has a more profound effect on cofactor function than the absence of amino acids Glu323 and Tyr324. In the
presence of 10 nM factor VaFF/MI, the rate of thrombin forma-

tion was ⬃180 mOD/min (Fig. 8, filled triangles); this rate is
25-fold smaller than the rate of thrombin generation in the
presence of wild type recombinant factor Va (⬃4500 mOD/min,
Fig. 8, filled squares). However, when comparing prothrombinase activity per nM enzyme used, and assuming a 1:1 stoichiometry between factor Va and factor Xa, the activity of the
double mutant when used at 10 nM (5 nM prothrombinase) was
36 mOD䡠min⫺1䡠nM⫺1, whereas the activity of the wild type
molecule was 4500 mOD䡠min⫺1䡠nM⫺1 (1 nM prothrombinase).
These data show a 125-fold decrease in activity of the double
mutant when used at saturating concentrations compared
with the wild type molecule. Altogether, our data suggest
that whereas the remaining binding site for factor Xa on the
light chain of the cofactor may be able to partially compensate for the absence of residues Glu323 and Tyr324, the absence of amino acids Glu330 and Val331 from the heavy chain
of the recombinant molecule appears more difficult to overcome. However, absence of all 4 amino cannot be efficiently
overcome by the binding site(s) on the light chain, resulting
in a factor Va molecule with severely impaired cofactor activity. Thus, the binding site(s) from the light chain of the
molecule can increase factor Xa activity independently of the
binding site from the heavy chain as previously suggested
(23).
The fact that an increase in the concentration of factor
VaFF/MI is required to obtain a weak cofactor effect demonstrates 1) a weakened interaction of the mutant cofactor with
factor Xa and 2) that discrete amino acids from both chains of
factor Va must interact with factor Xa in order to achieve the
dramatic increase in the catalytic efficiency of prothrombinase when compared with factor Xa alone; replacement of the
specific amino acids with residues containing a different
functional group results in the elimination of the contribution
of those amino acids to the activity of prothrombinase. It is
noteworthy that our data do not exclude the contribution of
another portion of the heavy chain to the interaction with
factor Xa as suggested earlier (49, 50). However, amino acids
Glu323, Tyr324, Glu330, and Val331 from the heavy chain of
factor Va appear to be critical for the interaction of the
cofactor with the enzyme and contribute a major binding site
for factor Xa.
DISCUSSION

By using a systematic peptide approach and employing both
protein chemistry and molecular biology approaches, we have
demonstrated that amino acids Glu323, Tyr324, Glu330, and
Val331 located on the A2 domain of factor V are crucial for
expression of factor Va cofactor activity. The region 323–331 of
the heavy chain of factor Va containing these 4 amino acid
residues was conserved throughout evolution, being 100% identical between species (17, 51–53). It is not yet known if the
same amino acid residues are responsible for both the cofactor
and effector functions of factor Va or different amino acids are
involved in the two processes.
Factor Xa alone possesses the catalytic machinery for cleavage and activation of prothrombin; however, its interaction
with factor Va and a membrane surface are required to obtain
a physiologically relevant rate for catalysis. Membrane-bound
factor Xa alone activates prothrombin following two sequential
cleavages: Arg271 followed by cleavage at Arg320 (54 –56). These
cleavages proceed through the intermediate prethrombin 2 and
produce ␣-thrombin and the activation fragment, fragment 1䡠2.
The interaction of factor Va with factor Xa and its incorporation into the prothrombinase complex alters the order and the
rate of peptide bond cleavages, resulting in the formation of an
active intermediate, meizothrombin (first cleavage at Arg320),
followed by the formation of fragment 1䡠2 and ␣-thrombin
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(cleavage at Arg271) (7, 54 –56). The factor Va effect on factor
Xa, besides reversing the order of cleavages during prothrombin activation, is also manifested by the increase in the overall
kcat of the prothrombin, activating reaction by 3,000-fold. The
dramatic effect of factor Va on the catalytic machinery of factor
Xa is yet to be understood at the molecular level. A recent study
using recombinant mutant prothrombin molecules has shown
that whereas the catalytic efficiency of factor Xa for cleavage at
Arg320 is increased by ⬃20,000-fold in the presence of factor Va,
the catalytic efficiency of the enzyme for cleavage at the Arg271
is only increased by 453-fold following binding to the cofactor
(57). However, the overall catalytic efficiency of the assembled
prothrombinase for cleavage at each site separately was similar. Thus, cleavage at Arg320 largely benefits from the interaction of the cofactor with factor Xa when compared with cleavage at Arg271 (57). As a consequence, it appears that
incorporation of factor Va into prothrombinase results in the
rearrangement of the prothrombin molecule in such a manner that cleavages at Arg320 and Arg271 by the factor Vafactor Xa complex independently become more favorable for
catalysis by prothrombinase than by membrane-bound factor
Xa. This rearrangement of the prothrombin molecule upon its
incorporation into the complex and its interaction with factor
Va and factor Xa was previously suggested following the
determination of the x-ray crystal structure of prethrombin 2
(58).
The binding of factor Va to factor Xa involves both chains of
the cofactor (11, 22–24). Whereas the binding site on the light
chain of factor Va remains to be identified, the binding site on
the heavy chain of the cofactor has been the object of intense
investigation. Because APC and plasmin inactivate the cofactor
following limited proteolysis of the heavy chain and dissociation of a portion of the molecule (25–28), several studies have
attempted to identify amino acid regions from the cofactor that
are important for its interaction with factor Xa. The regions
studied were usually located around the inactivating cleavage
sites of the cofactor or comprised an entire region located between two cleavage sites. A binding site for factor Xa was
reported within amino acid residues 493–506 of the heavy
chain (49, 50). We have previously suggested that a binding site
for factor Xa is located within amino acid region 307–348 of the
heavy chain of factor Va (28). We have next focused on this
region of the cofactor, because our findings suggested that
whereas cleavage of the heavy chain by plasmin at Arg348 is of
no consequence for the activity of the cofactor, cleavage by APC
at Arg306 or by plasmin at Lys309, Lys310, and Arg313, which are
all membrane-dependent, resulted in rapid and complete inactivation of factor Va (26, 28). Thus, this region of factor Va,
which most likely undergoes conformational rearrangement(s)
upon binding of the cofactor to a cell surface at the place of
vascular injury, contains several amino acids that are important for its incorporation into prothrombinase. Using overlapping peptides from the region 307–351, we have recently identified a nonapeptide containing amino acid residues 323–331
(AP4⬘) that represents a binding site for factor Xa. We have
further shown that the peptide interferes with the binding of
factor Va to [OG488]-EGR-hXa and can induce a “cofactor” effect
in the absence of factor Va, increasing the catalytic efficiency of
the enzyme by 4-fold when used at high concentrations (29). In
the present study, the use of overlapping pentapeptides from
AP4⬘ led to the identification of 4 amino acids located at its
extremities that are required for its overall activity. Recombinant molecules mutated at the specific sites confirmed
our findings.
The measure of the factor Va cofactor effect on factor Xa
when using the recombinant factor Va molecules and an assay
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measuring ␣-thrombin generation is usually determined by the
extent of the increase in the rate of ␣-thrombin formation.
Thus, the experiments using recombinant molecules cannot
distinguish between binding and effector function of factor Va.
The identification of the 4 amino acids described herein and
their putative function within the factor Va molecule was based
purely on the experiments using synthetic peptides. The experiments using recombinant molecules were only confirmatory
and can only attest to their importance within the overall
structure of the cofactor. Our data show that whereas peptide
A5V was able to interfere with the fluorescent anisotropy of
[OG488]-EGR-hXa, E5A had no significant effect on the fluorescent anisotropy of the enzyme. In contrast, whereas E5A alone
was able to increase the catalytic efficiency of the enzyme
toward prothrombin, peptide A5V was unable to produce a
similar effect. Since a perturbation of the signal of membranebound [OG488]-EGR-hXa (positive or negative) is usually correlated with direct binding (4, 5, 29, 30), overall the data
suggest that whereas amino acids Glu323 and Tyr324 alone may
contribute to the cofactor effect of factor Va (i.e. increase in the
catalytic efficiency of factor Xa), residues Glu330 and Val331
may be responsible for the high affinity interaction between the
cofactor and the enzyme on the membrane surface.
The reporter group Oregon Green 488 is attached to a chloromethyl ketone, which is covalently linked to the histidine
located in the active site of the enzyme (59, 60). Its intensity is
only perturbed in the presence of peptide A5V, which, when
tested alone, does not have any effect on the catalytic efficiency
of the enzyme. In contrast, peptide E5A, which increases the
activity of factor Xa toward prothrombin, does not have any
significant effect on the fluorescent anisotropy of the probe
attached to the active site of the enzyme. Thus, the changes in
the structure of factor Xa induced by E5A are different from the
changes induced on the molecule by A5V. Using recombinant
molecules, we have validated the data obtained with synthetic
peptides, and we have shown that under similar experimental
conditions, factor VaFF had consistently higher cofactor activity
than factor VaMI, but both recombinant molecules had impaired cofactor activity when compared with the wild type
cofactor. Thus, under any conditions employed, the binding site
on the light chain together with any remaining binding site
from the heavy chain is more efficient in increasing factor Xa
catalytic activity in the presence of amino acid residues Glu330
and Val331 than in the presence of amino acids Glu323 and
Tyr324. However, lack of all 4 amino acids results in a factor Va
molecule (factor VaFF/MI) that is severely deficient in its cofactor activity.
In the activity assays described here, the exact concentration
of each recombinant molecule used was of crucial importance
for the validation of our experiments, since impaired activity of
the recombinant molecules could be explained by the wrong
concentration used in the assay. An alternative explanation for
the decreased activities of the mutant factor Va molecules
could also be the fact that the recombinant molecules have
altered conformation, due to the change in the amino acid side
chain, which will ultimately impair their cofactor function.
Finally, the reason for impaired cofactor activity could be the
lack of the critical amino acids required for proper cofactor
function. In order to eliminate the first two possibilities, since
the latter explanation is the ultimate desired effect of our
experiments, the concentration of each molecule prior to all
assays was calculated using an ELISA recently developed in
our laboratory. All molecules were recognized with similar
affinities by the detecting antibodies, and SDS-PAGE analysis
did not reveal any electrophoretic abnormalities between normal plasma factor Va and the recombinant factor Va molecules.
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Further, we have made three conservative and one nonconservative mutation in such a manner that the entire conformation
of the recombinant factor V molecules possesses a tertiary
conformation as close as possible to the wild type factor Va
molecule. Since the cofactor activity of the recombinant wild
type factor Va molecule was similar to the activity of the
plasma-derived cofactor, we must conclude that 1) the concentrations of the recombinant factor Va molecules obtained from
the ELISA were accurate, and 2) the recombinant molecules
were properly folded. As a conclusion, impaired cofactor effect
of the mutant molecules is the consequence of the mutations.
All of these findings can be offered as arguments against generalized conformational change phenomena resulting in impaired cofactor activity. Further, several studies using recombinant factor V and factor V mutants have been performed by
various investigators using methodologies similar to ours (45–
48). No problems with the conformation of the recombinant
proteins have yet been reported. Thus, any difference observed
in the cofactor activities of the recombinant mutant molecules
is a direct consequence of the specific mutations. Altogether,
our data would suggest that amino acids Glu323, Tyr324, Glu330,
and Val331 are critical for the high affinity interaction of factor
Va with factor Xa on the membrane surface and provide a
reasonable starting point for a systematic investigation of the
amino acids that play crucial role for the expression of cofactor
activity. Finally, it is important to note that the possibility that
the mutant molecules have a weakened chain-chain interaction
because of the mutations resulting in a weaker interaction
between factor Va and factor Xa could not be excluded by
our studies.
As stated earlier, our data do not exclude the presence of
another binding site for factor Xa on the heavy chain of the
cofactor. The existence of a binding site for the enzyme was
suggested between amino acid residues 493 and 506 (49, 50). A
peptide containing these amino acids was found to inhibit
prothrombinase activity in a system using purified reagents
with an IC50 of 3 M. Kinetic analyses of the inhibition pattern
suggested a mixed type of inhibition. The inhibitory peptide
also interfered with the amidolytic activity of the enzyme toward a chromogenic substrate when used at high concentrations and was also found to interact with prothrombin. Thus, it
was not clear if the inhibitory peptide inhibited factor Xa or
prothrombin interaction with factor Va or if the peptide interfered with the binding of the cofactor to the phospholipid bilayer. Further, when the inhibitory peptide was amidated at
the COOH terminus or when a glutamine was substituted for
an arginine at the carboxyl terminus, its inhibitory activity was
lost (49, 50). It is thus possible that Arg506 from factor Va or its
surrounding amino acids may also provide for an interactive
site with factor Xa, albeit this interaction with the enzyme may
be secondary to the interaction of factor Xa with the peptide
containing amino acid residues 323–331.
In conclusion, our data identify amino acid residues Glu323,
Tyr324, Glu330, and Val331 from the factor Va heavy chain to be
essential for expression of optimum factor Va cofactor function.
A synthetic peptide containing these amino acids that will
inhibit cofactor activity will have the same effect as inhibiting
factor Xa and/or ␣-thrombin directly and may thus be a potent
anticoagulant with few or no side effects, since it is unlikely
that this peptide will interfere with the functions of any other
protein of the blood clotting cascade.
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